Completed PHASE1 INTERVENTIONAL 2-arm NCT05824091

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Trial in Healthy Adults to Evaluate the Safety, Tolerability, and PK of MK-7762

Sponsor: Gates Medical Research Institute

Conditions Tuberculosis

Interventions MK-7762 (TBD09) Placebo

Updated 6 times since 2023 Last updated: Jul 25, 2024 Started: Feb 23, 2023 Primary completion: Mar 26, 2024 Completion: Mar 26, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05824091, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Gates Medical Research Institute, it has been updated 6 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Jul 2025 [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

May 2023 — Jun 2024 [monthly]

Recruiting PHASE1

First recorded

Feb 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gates Medical Research Institute
Merck Sharp & Dohme LLC

Data source: Gates Medical Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States